Loading…
Reported covered position: Special Assistant, National Security Council; Special Assistant, International Trade Administration, Dept of Commerce; Policy Advisor, Office of the Deputy Chief of Staff, Executive Office of the President; Confidential Assistant, Dept of Commerce
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NEVRO CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTISSUE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Source: Senate LDA
| CATALYST PHARMACEUTICALS |
| 8 |
| 2023–2024 |
| COLLEGIUM PHARMACEUTICAL | 8 | 2023–2024 |
| ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY | 8 | 2023–2024 |
| GILEAD SCIENCES, INC. | 8 | 2023–2024 |
| GLAUKOS CORPORATION (FKA AVEDRO, INC.) | 8 | 2023–2024 |
| HARMONY BIOSCIENCES, LLC | 8 | 2023–2024 |
| INSTITUTE FOR GENE THERAPIES | 8 | 2023–2024 |
| LIVANOVA USA INC | 8 | 2023–2024 |
| MOMENTOUS | 8 | 2023–2024 |
| NEVRO CORPORATION | 8 | 2023–2024 |
| ORGANON & CO. | 8 | 2023–2024 |
| PHARMING HEALTHCARE, INC. | 8 | 2023–2024 |
| STERIS CORPORATION | 8 | 2023–2024 |
| SUPERNUS PHARMACEUTICALS, INC. | 8 | 2023–2024 |
| TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION (FKN TENNESSEE FARM BR. ASSN.) | 8 | 2023–2024 |
| TERUMO BCT | 8 | 2023–2024 |
| THE ALLERGY, ASTHMA & SINUS CENTER | 8 | 2023–2024 |
| U.S. RENAL CARE | 8 | 2023–2024 |
| WE WORK FOR HEALTH | 8 | 2023–2024 |
| AURION BIOTECH | 7 | 2023–2024 |
| Eagle Pharmaceuticals, Inc. | 7 | 2023–2024 |
| ILLUMINA, INC. | 7 | 2023–2024 |
| SPARK THERAPEUTICS, INC. | 7 | 2023–2024 |
| scPharmaceuticals Inc. | 7 | 2023–2024 |
| AMGEN, INC. | 6 | 2024 |
| ANIVIVE LIFESCIENCES | 6 | 2023–2024 |
| BIOTISSUE | 6 | 2024 |
| LIFEWARD (FORMERLY REWALK ROBOTICS, INC.) | 6 | 2023–2024 |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | 6 | 2024 |
| NEUROTECH PHARMACEUTICALS | 6 | 2024 |
| SPARC | 6 | 2024 |
| SSI GROUP | 6 | 2023–2024 |
| REVANCE THERAPEUTICS INC. | 5 | 2023–2024 |
| GENUS LIFESCIENCES | 4 | 2024 |
| SUMITOMO PHARMA CO., LTD. (FORMERLY SUNOVION PHARMACEUTICALS, INC.) | 4 | 2023–2024 |
| TEK84 | 4 | 2023–2024 |
| THERAGEN, INC. | 4 | 2024 |
| ENZYVANT THERAPEUTICS GMBH | 2 | 2023 |
| HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) | 2 | 2023 |
| IOR PARTNERS | 2 | 2023 |
| MASIMO | 2 | 2024 |
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Kidney PATIENT Act of 2023
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; H.R.5074 - Kidney PATIENT Act
Kidney PATIENT Act of 2023
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; H.R.5074 - Kidney PATIENT Act
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; H.R.5074 - Kidney PATIENT Act
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis; H.R.5074 - Kidney PATIENT Act
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Cameron’s Law
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Cameron’s Law
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Issues related to the development of therapies for rare diseases and sleep disorders; sleep health equity; drug pricing; and access to non-controlled medications. H.R.1350, Camerons Law. FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. H.R. 1805, Leos Law.
Safe Step Act
Client: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652; FTC regulation of biopharma mergers and acquisitions
Safe Step Act
Client: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Value-based pricing arrangements; MVP Act - HR 2666
ORPHAN Cures Act
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act. H.R. 5539, The ORPHAN Cures Act.
Restore Protections for Dialysis Patients Act
Client: U.S. RENAL CARE · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - HR 6860; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
HELP Copays Act
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act
HELP Copays Act
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act. H.R. 5539, The ORPHAN Cures Act.
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
HELP Copays Act
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act. H.R. 5539, The ORPHAN Cures Act.
HELP Copays Act
Client: HARMONY BIOSCIENCES, LLC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the implementation of Inflation Reduction Act Medicare Part D redesign policy. H.R. 830, S.1375, The HELP Copays Act
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: NEVRO CORPORATION · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Outpatient Surgery Quality and Access Act of 2023
Client: LIVANOVA USA INC · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Safe Step Act
Client: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652; FTC regulation of biopharma mergers and acquisitions
Safe Step Act
Client: HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
issues related to tissue products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROTECH PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to approval of combination products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCPHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
general issues of interest to pharmaceutical companies
Medicare reimbursement of pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLUMINA, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
issues related to the National Defense Authorization Act for FY 2025
issues related to health care diagnostics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to implementation of the Inflation Reduction Act of 2022, Issues relating to Medicare Part B and Medicare Part D drug pricing reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOMENTOUS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues Related to Defense and Human Performance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COLLEGIUM PHARMACEUTICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMING HEALTHCARE, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to FDA and rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUPERNUS PHARMACEUTICALS INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
issues related to the pharmaceutical industry
issues related to Medicare drug reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
General Issues of interest to pharmaceutical companies
Medicare reimbursement of pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STERIS CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
medical device manufacturing, servicing, and sterilization issues; FDA modernization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSTITUTE FOR GENE THERAPIES via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to the regulation of gene therapies; newborn screening; FDA appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to regulation of prescription drugs and biologics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BROOKDALE SENIOR LIVING INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
issues related to senior health care
issues related to senior housing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CATALYST PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
General FDA issues related to orphan drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOGEN INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to the pharmaceutical industry
Issues related to Medicare Part B and Part D
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES, LLC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to the development and approval of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to medication affordability and access
Issues related to Medicare ESRD benefit and chronic kidney disease management
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENUS LIFESCIENCES via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALLERGY, ASTHMA & SINUS CENTER via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
coverage of allergy treatment
issues related to the practice of allergy treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to domestic manufacturing; issues related to 340B; issues related to implementation of the Inflation Reduction Act and the Bipartisan Infrastructure Bill; Issues related to supply chain resilience.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION (FKN TENNESSEE FARM BR. ASSN.) via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
health care coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U.S. RENAL CARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACCURAY INCORPORATED via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to Medicare payment for/access to radiation therapy services
Issues related to Section 301 tariffs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to diabetes and cardiovascular disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLAUKOS CORPORATION (FKA AVEDRO, INC.) via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to medical device reimbursement
Issues related to FDA enforcement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TERUMO BCT via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Issues related to apheresis access and reimbursement
Issues related to supply chain constraints
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIVANOVA USA INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Issues related to epilepsy; Issues related to the importation of medical devices; issues related to telemedicine waivers
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4A
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERAGEN, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4T
Issues related to osteogenic bone growth stimulators
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROTECH PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to approval of combination products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TERUMO BCT via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to apheresis access and reimbursement
Issues related to supply chain constraints
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AURION BIOTECH via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to combination product development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Education regarding gene therapies/one-time treatments; policies and regulations impacting drugs for rare diseases and conditions; FDA modernization
Value-based pricing arrangements; MVP Act - HR 2666
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSTITUTE FOR GENE THERAPIES via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Issues related to the regulation of gene therapies; newborn screening; FDA appropriations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to medication affordability and access
Issues related to Medicare ESRD benefit and chronic kidney disease management
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLAUKOS CORPORATION (FKA AVEDRO, INC.) via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to medical device reimbursement
Issues related to FDA enforcement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTISSUE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
issues related to tissue products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOMENTOUS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues Related to Defense and Human Performance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMING HEALTHCARE, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to FDA and rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STERIS CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
medical device manufacturing, servicing, and sterilization issues; FDA modernization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CATALYST PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
General FDA issues related to orphan drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LIVANOVA USA INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to epilepsy; Issues related to the importation of medical devices; issues related to telemedicine waivers
Medicare beneficiary access to innovative medical technology; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act; Medicare beneficiary access to treatments for depression
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEVRO CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
U.S. RENAL CARE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to Medicare policies impacting ESRD; Medicare Secondary Payer Act - H.R. 6860/S.5018; ESRD Prospective Payment System; value-based care and alternative payment models; home dialysis
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACCURAY INCORPORATED via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to Section 301 tariffs
Issues related to Medicare payment for/access to radiation therapy services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
GENUS LIFESCIENCES via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION (FKN TENNESSEE FARM BR. ASSN.) via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
health care coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COLLEGIUM PHARMACEUTICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BROOKDALE SENIOR LIVING INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
issues related to senior housing
issues related to senior health care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALLERGY, ASTHMA & SINUS CENTER via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
issues related to the practice of allergy treatment
coverage of allergy treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to domestic manufacturing; issues related to 340B; issues related to implementation of the Inflation Reduction Act and the Bipartisan Infrastructure Bill; Issues related to supply chain resilience.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUPERNUS PHARMACEUTICALS INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
issues related to the pharmaceutical industry
issues related to Medicare drug reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCPHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
general issues of interest to pharmaceutical companies
Medicare reimbursement of pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
General Issues of interest to pharmaceutical companies
Medicare reimbursement of pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to implementation of the Inflation Reduction Act of 2022, Issues relating to Medicare Part B and Medicare Part D drug pricing reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLUMINA, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
issues related to the National Defense Authorization Act for FY 2025
issues related to health care diagnostics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to regulation of prescription drugs and biologics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES, LLC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to the development and approval of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EAGLE PHARMACEUTICALS INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · 4T
Medicare reimbursement issues
FDA issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOGEN INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to the pharmaceutical industry
Issues related to Medicare Part B and Part D
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · fourth_quarter · Q4
Issues related to diabetes and cardiovascular disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to domestic manufacturing; issues related to 340B; issues related to implementation of the Inflation Reduction Act and the Bipartisan Infrastructure Bill; Issues related to supply chain resilience.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERAGEN, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to osteogenic bone growth stimulators
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTISSUE via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
issues related to tissue products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MOMENTOUS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues Related to Defense and Human Performance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMING HEALTHCARE, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to FDA and rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STERIS CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
medical device manufacturing, servicing, and sterilization issues; FDA modernization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CATALYST PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
General FDA issues related to orphan drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SSI GROUP via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to health IT and medical records
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MASIMO via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · 3T
issues related to transparency and disclosure with financial entitie
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES, LLC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to the development and approval of therapies for rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEUROTECH PHARMACEUTICALS via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to approval of combination products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCPHARMACEUTICALS, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Medicare reimbursement of pharmaceuticals
general issues of interest to pharmaceutical companies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AURION BIOTECH via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to combination product development
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to implementation of the Inflation Reduction Act of 2022, Issues relating to Medicare Part B and Medicare Part D drug pricing reforms.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COLLEGIUM PHARMACEUTICAL via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUPERNUS PHARMACEUTICALS INC via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
issues related to the pharmaceutical industry
issues related to Medicare drug reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL DEVICE MANUFACTURERS ASSOCIATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
issues related to medical devices
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON & CO. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
General Issues of interest to pharmaceutical companies
Medicare reimbursement of pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INSTITUTE FOR GENE THERAPIES via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to the regulation of gene therapies; newborn screening; FDA appropriations
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to regulation of prescription drugs and biologics
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BROOKDALE SENIOR LIVING INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
issues related to senior housing
issues related to senior health care
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOGEN INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to Medicare Part B and Part D
Issues related to the pharmaceutical industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ARDELYX, INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to Medicare ESRD benefit and chronic kidney disease management
Issues related to medication affordability and access
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENUS LIFESCIENCES via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
issues related to pharmaceutical drugs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NEVRO CORPORATION via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Issues related to Medicare and Medicaid coverage and payment for chronic pain management devices; Issues related to spinal cord stimulation; Medicare beneficiary access to procedures performed in ambulatory surgical centers - HR 972/S 312, Outpatient Surgery Quality and Access Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE ALLERGY, ASTHMA & SINUS CENTER via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
coverage of allergy treatment
issues related to the practice of allergy treatment
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EAGLE PHARMACEUTICALS INC. via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
Medicare reimbursement issues
FDA issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION (FKN TENNESSEE FARM BR. ASSN.) via JEFFREY J. KIMBELL & ASSOCIATES, INC.
2024 · third_quarter · Q3
health care coverage
Filing targets: HOUSE OF REPRESENTATIVES, SENATE